[Analysis of patients with locally advanced gastric cancer undergoing gastrectomy after pre-operative chemotherapy including S-1].
To improve the prognosis of advanced gastric cancer, various adjuvant therapies were tried. We retrospectively examined 7 cases of gastrectomy after pre-operative chemotherapy using S-1+CDDP, and reported its effectiveness and the result. An adverse event of more than Grade 3 showed neutropenia in two cases. Anti-tumor effect on the imaging was found in 6 cases of PR and one case of SD. We performed gastrectomy within 4 weeks after completion of chemotherapy in each case. The histological antitumor effect was more than Grade 2 in four cases, but there was no complete response. We compared the overall survival of a patient of more than Grade 2 by histological antitumor effect under grade 1b. In the former, MST was 982 days and the two-year survival rate was 50.0%; in the latter, MST was 443 days and the two-year survival rate was 33.3%. We can perform pre-operative chemotherapy using S-1+CDDP and expect prognostic improvement for a histologically effective case of chemotherapy. If the utility of preoperative chemotherapy mainly with S-1 is proved in a phase III trial, this would appear to be a therapy of choice for advanced gastric cancer in future.
Kinouchi
Makoto
M
Division of Biological-regulation and Oncology, Graduate School of Medicine, Tohoku University.
Shibata
Chikashi
C
Miura
Koh
K
Okabe
Mitsunori
M
Andou
Toshinori
T
Kakyou
Masayuki
M
Saijou
Fumito
F
Haneda
Sho
S
Ogawa
Hitoshi
H
Unno
Michiaki
M
Sasaki
Iwao
I
D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004338:Drug Combinations; D005260:Female; D005743:Gastrectomy; D006801:Humans; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D010094:Oxonic Acid / Q000008:administration & dosage; D013274:Stomach Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D005641:Tegafur / Q000008:administration & dosage
D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D002945:Cisplatin